Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherContinuing Education (Invitation Only)

Bone Mineral Density – Clinical Relevance and Quantitative Assessment

Katherine Haseltine, Tariq Chukir, Pinar Smith, Justin Jacob, John Bilezikian and Azeez Farooki
Journal of Nuclear Medicine December 2020, jnumed.120.256180; DOI: https://doi.org/10.2967/jnumed.120.256180
Katherine Haseltine
1 Memorial Sloan Kettering Cancer Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tariq Chukir
1 Memorial Sloan Kettering Cancer Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pinar Smith
2 Icahn School of Medicine at Mount Sinai, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Jacob
1 Memorial Sloan Kettering Cancer Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Bilezikian
3 Columbia University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Azeez Farooki
1 Memorial Sloan Kettering Cancer Center, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DXA) is an internationally accepted standard-of-care screening tool used to assess fragility fracture risk. Society guidelines have recommended which populations may benefit from DXA screening and the use of the Fracture Risk Assessment Tool (FRAX®) to guide decisions regarding pharmacologic treatment for osteoporosis. According to the United States National Osteoporosis Foundation guidelines, postmenopausal women and men ≥50 years with osteopenic BMD warrant pharmacologic treatment if their FRAX-calculated 10-year probability of either a hip fracture is ≥3% or a major osteoporotic fracture is ≥20%. Patients with osteoporosis defined by a clinical event, namely a fragility fracture, or with an osteoporotic BMD should also be treated. Patients who are treated for osteoporosis should be monitored regularly to track expected gains in BMD by serial DXA scans. With some drug therapies, BMD targets can be reached whereby further improvements in BMD are not associated with further reductions in fracture risk. While reaching this target might suggest a stopping point for therapy, the reversibility of most treatments for osteoporosis, except for the bisphosphonates, has dampened enthusiasm for this approach. In the case of denosumab, it is now apparent that stopping therapy at any point can lead to an increase in multiple fracture risk. For patients who do not respond to antiosteoporosis pharmacologic therapy, with an improvement in BMD or an incident fragility fracture, other intervening issues, such as vitamin D deficiency, and/or compliance should be considered.

  • Bone
  • Bone Densitometry
  • Endocrine
  • DXA
  • FRAX
  • bone mineral density
  • fracture risk
  • osteoporosis
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bone Mineral Density – Clinical Relevance and Quantitative Assessment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Bone Mineral Density – Clinical Relevance and Quantitative Assessment
Katherine Haseltine, Tariq Chukir, Pinar Smith, Justin Jacob, John Bilezikian, Azeez Farooki
Journal of Nuclear Medicine Dec 2020, jnumed.120.256180; DOI: 10.2967/jnumed.120.256180

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bone Mineral Density – Clinical Relevance and Quantitative Assessment
Katherine Haseltine, Tariq Chukir, Pinar Smith, Justin Jacob, John Bilezikian, Azeez Farooki
Journal of Nuclear Medicine Dec 2020, jnumed.120.256180; DOI: 10.2967/jnumed.120.256180
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The role of nuclear medicine in the clinical management of benign thyroid disorders. Part 1. Hyperthyroidism
Show more Continuing Education (Invitation Only)

Similar Articles

Keywords

  • Bone
  • Bone Densitometry
  • Endocrine
  • DXA
  • FRAX
  • bone mineral density
  • fracture risk
  • osteoporosis
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire